DTB podcast
Summary: From June 2023, all our podcasts will move to https://dtbbmj.podbean.com. You can continue with your subscription on your favourite podcast App. For 50 years, Drug and Therapeutics Bulletin (DTB) has provided rigorous and independent evaluations of, and practical advice on, individual treatments and the overall management of disease for doctors, pharmacists and other healthcare professionals. DTB has always been wholly independent of the pharmaceutical industry, Government and regulatory authorities. DTB is also free of advertising and other forms of commercial sponsorship. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page - https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309. * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.
- Visit Website
- RSS
- Artist: BMJ Group
- Copyright: 643134
Podcasts:
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the June 2022 issue of DTB. They discuss the impact that the cessation of spirometry services in primary care has had on diagnosing obstructive lung disease (https://dtb.bmj.com/content/60/6/82). They highlight two separate patient safety incident reports from the Healthcare Safety Investigation Branch - confusion over the prescribed dose of oral morphine solution and the harm caused by a standard therapeutic dose of paracetamol in a frail older person (https://dtb.bmj.com/content/60/6/84). The editors also talk about an article on serotonin syndrome (https://dtb.bmj.com/content/60/6/88). Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening. Read the June issue: https://dtb.bmj.com/content/60/6
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the May 2022 issue of DTB. They talk about drug bulletins across the world and the role of the International Society of Drug Bulletins in supporting bulletins and ensuring that they are intellectually and financially independent (https://dtb.bmj.com/content/60/5/66). They review a study that assessed the use of mirtazapine for treating agitation in people with dementia (https://dtb.bmj.com/content/60/5/68). The editors also discuss the evidence behind two new oral antivirals that have been licensed for the treatment of covid-19 (https://dtb.bmj.com/content/60/5/73). Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the April 2022 issue of DTB. They talk about DTB's 60th anniversary, the importance of independent scrutiny of new medicines and the need to question how medicines are licensed and used (https://dtb.bmj.com/content/60/4/50). They highlight the benefits of a comprehensive national register of conflicts of interest and discuss a study that compared a quadpill containing low doses of four antihypertensive agents with a standard dose of irbesartan (https://dtb.bmj.com/content/60/4/56). They also review a study that assessed clinicians' awareness of the harms from long-term use of nitrofurantoin (https://dtb.bmj.com/content/60/4/59) and provide an overview of an article on managing hypertension in pregnancy (https://dtb.bmj.com/content/60/4/60). The editors also look back at the very first issue of DTB that was published on 20th April 1962 (https://dtb.bmj.com/content/s1-1/1). Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the March 2022 issue of DTB. They talk about paracetamol and its effect on blood pressure and discuss progress on moving to inhalers that have less of an impact on the environment (https://dtb.bmj.com/content/60/3/34). The editors review a study that examined harms from medicines (https://dtb.bmj.com/content/60/3/37) and discuss the use of naldemedine in the management of opioid-induced constipation (https://dtb.bmj.com/content/60/3/39). Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the February 2022 issue of DTB. They talk about some of the details from a national report on overprescribing and discuss its implications (https://dtb.bmj.com/content/60/2/18). The editors review a study that highlighted overprescribing of short-acting beta agonists in people with asthma (https://dtb.bmj.com/content/60/2/21). They also discuss an article on prescribing for women of childbearing age who have inflammatory bowel disease and managing medicines during pregnancy (https://dtb.bmj.com/content/60/2/24). Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the January 2022 issue of DTB. They discuss the UK Medicines and Healthcare products Regulatory Agency's decision to license the oral antiviral drug molnupiravir (Lagevrio) and the paucity of publicly available clinical trial data - https://dtb.bmj.com/content/60/1/2. The editors talk about a study that highlighted potentially inappropriate prescribing in middle-aged adults - https://dtb.bmj.com/content/60/1/6. They also review an article on some of the challenges facing people when they try to stop taking antidepressants - https://dtb.bmj.com/content/60/1/7. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the December issue of DTB. They discuss a recently published national report on overprescribing of medicines. The editors talk about a study that assessed the accuracy of home blood pressure monitors (https://dtb.bmj.com/content/59/12/179) and highlight a safety alert on topical steroid withdrawal reactions (https://dtb.bmj.com/content/59/12/184). They also review an article on the US Food and Drug Administration's decision to license bremelanotide and flibanserin for 'hypoactive sexual desire disorder’ in women (https://dtb.bmj.com/content/59/12/185). Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the November issue of DTB. They discuss a French initiative that identifies a range of drugs that should not be prescribed (https://dtb.bmj.com/content/59/11/162) and talk about the difficulty of assessing whether patients' penicillin allergy records are correct (https://dtb.bmj.com/content/59/11/163). They also review an article on the use of romosozumab for osteoporosis (https://dtb.bmj.com/content/59/11/169). They begin by highlighting DTB's blog for World Evidence-Based Healthcare Day (https://worldebhcday.org/) on the role of independent drug bulletins during an info-demic. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the October issue of DTB. They discuss the impact of making desogestrel contraceptives available for purchase from pharmacies (https://dtb.bmj.com/content/59/10/146) and talk about the role of percutaneous coronary intervention in patients with stable ischaemic heart disease (https://dtb.bmj.com/content/59/10/150). They also review an article about managing migraine in pregnancy (https://dtb.bmj.com/content/59/10/152). They begin by highlighting the decision to remove pregabalin from the Northern Ireland formulary for neuropathic pain. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the September issue of DTB. They discuss the US FDA's controversial decision to license aducanumab for Alzheimer's disease (https://dtb.bmj.com/content/59/9/130) and consider barriers to prescribing shorter courses of antibiotics in primary care (https://dtb.bmj.com/content/59/9/131). The editors also highlight the impact that some medicines have on oral health and dental treatment (https://dtb.bmj.com/content/59/9/135). Before all of that though, the recent NICE's guideline on shared decision making. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the August issue of DTB (https://dtb.bmj.com/content/59/8). The editors talk about the MHRA's decision to reverse the EMA's decision and allow boron-containing chloramphenicol eye drops to be used in children aged below 2 years. They discuss a scheme in England that allows hospital staff to refer patients who would benefit from extra guidance around their medicines regimen for support from a community pharmacy (https://dtb.bmj.com/content/59/8/114). They also highlight the risk from concurrent opioid and benzodiazepine use (https://dtb.bmj.com/content/59/8/116), and talk about home blood pressure monitoring (https://dtb.bmj.com/content/59/8/119). Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the July issue of DTB. The editors catch up on developments with proposals for all doctors in the UK to provide financial and non-financial declarations of interest. They discuss the problem of boron in chloramphenicol eye drop products and the impact on treating children aged under 2 years (https://dtb.bmj.com/content/59/7/98). The editors also talk about PPIs for persistent throat symptoms (https://dtb.bmj.com/content/59/7/102), the dose of folic acid for use with methotrexate (https://dtb.bmj.com/content/59/7/103) and a case of a patient who developed severe hypophosphataemia with an oral bisphosphonate (https://dtb.bmj.com/content/59/7/107). Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) review the June issue of DTB. The list of articles mentioned in this podcast: The Editorial “COVID-19 vaccination in pregnancy” - https://dtb.bmj.com/content/59/6/82 DTB select “Stepping down asthma treatment” - https://dtb.bmj.com/content/59/6/85 Review “Prescribing for pregnancy: managing diabetes” - https://dtb.bmj.com/content/59/6/88 Republished case report “Euglycaemic diabetic ketoacidosis in a 43-year-old woman with type 2 diabetes mellitus on SGLT-2 inhibitor (empagliflozin)” - https://dtb.bmj.com/content/59/6/93 Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) review the May issue of DTB. In light of the "First do no harm" report, the editorial discusses the need for a mandatory register of payments made by pharmaceutical and medical device companies to healthcare professionals, healthcare organisations and patient support organisations (https://dtb.bmj.com/content/59/5/66). The editors talk about the BTS guideline on long-term use of macrolides (https://dtb.bmj.com/content/59/5/67). The main article explores the use of CAR T-cell therapy (https://dtb.bmj.com/content/59/5/73) and the case report is of a patient who developed quinidine hypersensitivity (https://dtb.bmj.com/content/59/5/77). Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) review the April issue of DTB. The editorial discusses variability in the management of people with severe asthma (https://dtb.bmj.com/content/59/4/50). The editors talk about a summary of an article on changes in prescribing of statins (https://dtb.bmj.com/content/59/4/53). The main article explores the use of aspirin for pre-eclampsia (https://dtb.bmj.com/content/59/4/56) and the case report is of a patient who developed omeprazole-induced hypomagnesaemia (https://dtb.bmj.com/content/59/4/60). Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
